Latest news with #SheetalSapale
News18
4 days ago
- Business
- News18
Mounjaro Market Heavyweight Among Anti-Obesity Drugs, Grabs Early Lead Over Wegovy In India
Last Updated: In July 2025 alone, Wegovy clocked Rs 7 crore in sales with around 5,000 injections, while Mounjaro posted Rs 47 crore in sales, with close to 1,57,000 units—almost 30 times more India's booming weight-loss injection market is witnessing a sharp divide. While Novo Nordisk's recently launched Wegovy is still finding its footing, Eli Lilly's Mounjaro continues to dominate, the latest sales data shows. According to data from research firm Pharmarack, the GLP-1 (glucagon-like peptide-1 receptor agonist) drug segment has more than doubled in value over the last two years, growing from Rs 288 crore in July 2023 to Rs 606 crore in July 2025. Data shows that semaglutide (Wegovy), launched in July, and tirzepatide, launched in March, continue to drive the growth of the market. In July 2025 alone, Wegovy clocked Rs 7 crore in sales and sold around 5,000 injections, while Mounjaro posted Rs 47 crore in sales, selling approximately 1,57,000 units—almost 30 times more. 'While we see the numbers for Wegovy and Mounjaro picking up month on month, we need to understand that Eli Lilly and Novo Nordisk have done a lot of market priming work with health specialists. These specialists have helped them identify the right set of patients," Sheetal Sapale, vice-president, commercial, at Pharmarack, told News18. 'Though Wegovy has a strong prescriber base because of Rybelsus (oral semaglutide tablets), substantial promotion may be needed to reach the Mounjaro patient base for the injectable market." Rybelsus is an oral tablet, whereas Wegovy is an injectable form of the active pharmaceutical ingredient called semaglutide, which is responsible for weight loss and blood glucose management. Why is Mounjaro leading? While Mounjaro has an early mover advantage, as it was launched a quarter earlier than Wegovy, experts believe that one of the critical factors behind the gap in demand is pricing. Wegovy is more expensive than Mounjaro, with a monthly dosage priced between Rs 17,000 and Rs 26,000, compared to Mounjaro's cost of Rs 14,000 to Rs 17,500. Experts believe Mounjaro's edge isn't just due to timing or pricing. Dr Sambit Dash, associate professor, biochemistry at MUCM Malaysia, believes that Mounjaro is currently ahead for several reasons. He points out that 'its slightly higher efficacy in weight loss compared to Wegovy has made it a preferred choice among prescribers". Dash believes 'the earlier launch gave it a first-mover advantage, and Mounjaro's growing adoption in countries like the UK has further reinforced its reputation. Also, Eli Lilly's aggressive marketing strategy has helped make the brand more recognisable, with Mounjaro becoming a more familiar name globally." Over the past year, celebrities such as Rosie O'Donnell, Eric Stonestreet, and Renee Graziano have publicly acknowledged using Mounjaro to manage their weight, driving further interest and awareness around the drug. The brand has also been frequently mentioned in lifestyle outlets, talk shows, and social media platforms. However, here comes a clinical perspective. In medical terms, Mounjaro appears to have a slight edge as well. A 2025 meta-analysis comparing tirzepatide (Mounjaro) and semaglutide (Wegovy) found that patients on tirzepatide lost on average 11.4% of their body weight, compared to 7.3% for those on semaglutide. In a 72-week randomised controlled trial, published in the New England Journal of Medicine, involving adults with obesity but without diabetes, Mounjaro users achieved an average weight loss of 20.2%, whereas Wegovy users saw a 13.7% reduction. Battle not over for Wegovy Despite the initial gap, some experts believe Wegovy still has strong growth potential. Renowned endocrinologist Dr Anoop Misra, chairman, Fortis C-DOC, acknowledges that Mounjaro currently outperforms Wegovy, but the latter will gear up soon. 'Mounjaro is more effective for weight loss and has a head start over Wegovy. At the same time, Wegovy, having all the properties of a powerful molecule, is likely to scale up soon." Get breaking news, in-depth analysis, and expert perspectives on everything from politics to crime and society. Stay informed with the latest India news only on News18. Download the News18 App to stay updated! tags : health Obesity Weight Loss view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Economic Times
4 days ago
- Business
- Economic Times
Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months
Synopsis The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-on-month doubling of sales continues, Mounjaro's revenue could cross Rs 500 crore by March, experts estimate. Reuters A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly. US drugmaker Eli Lilly's weight-loss drug Mounjaro (tirzepatide) has crossed Rs 100 crore in sales in India in just four months of launch, making it one of the country's fastest-growing prescription brands ever by value. The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-on-month doubling of sales continues, Mounjaro's revenue could cross Rs 500 crore by March, experts estimate. After that, there could be a price erosion in the segment, as generic versions of rival GLP1 molecule semaglutide, branded as Wegovy by Danish drugmaker Novo Nordisk, are expected to flood the market. Drugs that have seen similar burgeoning growth in the past include some in the anti-diabetic category, such as Januvia (sitagliptin), Trajenta (linagliptin), Jardiance (empagliflozin), Forxiga (dapagliflozin), and Rybelsus (oral semaglutide). Wegovy, launched in early June, also saw a doubling of sales numbers with cumulative sales of the first two months at Rs 10 crore. 'Though Wegovy has a strong prescriber base because of Rybelsus (oral semaglutide), substantial promotion may be needed to reach the Mounjaro patient base for the injectable market,' said Sheetal Sapale, vice president, commercial, at PharmaTrac. Mounjaro, which was launched in late March, has so far garnered a significant patient base, selling about 160,000 units versus Wegovy's 5,000. 'As competition gets tough and branded generics come into the market, volume sales will be a major decider of who goes ahead in the race as this extent of value creation will be challenging,' Sapale said. Industry experts and doctors said the higher weight loss efficacy of 20-22% from Mounjaro compared to Wegovy's 16-18% and a lower price point make it more attractive to many patients. Wegovy is currently priced between Rs 17,345 to Rs 26,050 per pen-filled injection, which is a month's dose of four once-a-week shots. Mounjaro, which is also given on a weekly basis, is priced at Rs 14,000 to Rs 17,500 for a month's Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai, said Mounjaro has captured a major share of the market so far due to their early launch and higher weight loss efficacy. 'Diabetes patients prefer Wegovy, while non-diabetes obese patients prefer Mounjaro,' he said. Apart from chronic weight management in obesity, Mounjaro is also indicated to improve glycaemic control in adults with type-2 diabetes mellitus, which is an additional benefit. Wegovy is used for obesity treatment and selectively in reduction in risk of major adverse cardiovascular events (MACE).
Time of India
4 days ago
- Business
- Time of India
Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel US drugmaker Eli Lilly 's weight-loss drug Mounjaro (tirzepatide) has crossed Rs 100 crore in sales in India in just four months of launch, making it one of the country's fastest-growing prescription brands ever by drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker this month-on-month doubling of sales continues, Mounjaro's revenue could cross Rs 500 crore by March, experts that, there could be a price erosion in the segment, as generic versions of rival GLP1 molecule semaglutide, branded as Wegovy by Danish drugmaker Novo Nordisk, are expected to flood the that have seen similar burgeoning growth in the past include some in the anti-diabetic category, such as Januvia (sitagliptin), Trajenta (linagliptin), Jardiance (empagliflozin), Forxiga (dapagliflozin), and Rybelsus (oral semaglutide).Wegovy, launched in early June, also saw a doubling of sales numbers with cumulative sales of the first two months at Rs 10 crore.'Though Wegovy has a strong prescriber base because of Rybelsus (oral semaglutide), substantial promotion may be needed to reach the Mounjaro patient base for the injectable market,' said Sheetal Sapale, vice president, commercial, at which was launched in late March, has so far garnered a significant patient base, selling about 160,000 units versus Wegovy's 5,000.'As competition gets tough and branded generics come into the market, volume sales will be a major decider of who goes ahead in the race as this extent of value creation will be challenging,' Sapale experts and doctors said the higher weight loss efficacy of 20-22% from Mounjaro compared to Wegovy's 16-18% and a lower price point make it more attractive to many is currently priced between Rs 17,345 to Rs 26,050 per pen-filled injection, which is a month's dose of four once-a-week shots. Mounjaro, which is also given on a weekly basis, is priced at Rs 14,000 to Rs 17,500 for a month's Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai, said Mounjaro has captured a major share of the market so far due to their early launch and higher weight loss efficacy.'Diabetes patients prefer Wegovy, while non-diabetes obese patients prefer Mounjaro,' he from chronic weight management in obesity, Mounjaro is also indicated to improve glycaemic control in adults with type-2 diabetes mellitus, which is an additional benefit. Wegovy is used for obesity treatment and selectively in reduction in risk of major adverse cardiovascular events (MACE).
Economic Times
5 days ago
- Health
- Economic Times
Novo Nordisk's Wegovy, Mounjaro sales in India double on month in July
Synopsis Sales of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in India doubled in July, according to Pharmarack data. Wegovy, launched in June, saw sales more than double to 5,000 units, while Mounjaro sales also doubled to 157,000 units. Mounjaro's sales have soared 15 times since its March launch in India. IANS Representational Image Sales of Danish drugmaker Novo Nordisk's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month earlier, data from research firm Pharmarack showed on Thursday. Demand for the blockbuster anti-obesity drugs, which help control blood sugar and slow digestion, has been on an upswing in the world's most populous nation. Sales of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data showed. Mounjaro sales also doubled month-on-month to 157,000 units or 470 million rupees. "Though Wegovy has a strong prescriber base because of Rybelsus, substantial promotion may be needed to reach the Mounjaro patient base for the injectable market," Pharmarack's Vice President (Commercial) Sheetal Sapale said in a statement. In India, Novo has been selling oral semaglutide pills under the brand name Rybelsus since 2022 for type 2 diabetes. Mounjaro's sales have soared 15 times since March, when the drug was launched in India. ($1 = 87.6790 Indian rupees)
Time of India
5 days ago
- Business
- Time of India
Novo Nordisk's Wegovy, Mounjaro sales in India double on month in July
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month earlier, data from research firm Pharmarack showed on for the blockbuster anti-obesity drugs , which help control blood sugar and slow digestion, has been on an upswing in the world's most populous of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data sales also doubled month-on-month to 157,000 units or 470 million rupees."Though Wegovy has a strong prescriber base because of Rybelsus, substantial promotion may be needed to reach the Mounjaro patient base for the injectable market," Pharmarack's Vice President (Commercial) Sheetal Sapale said in a India, Novo has been selling oral semaglutide pills under the brand name Rybelsus since 2022 for type 2 diabetes Mounjaro's sales have soared 15 times since March, when the drug was launched in India.($1 = 87.6790 Indian rupees)
